Core Insights - CorMedix Therapeutics announced interim results from a real-world evidence study of DefenCath, showing significant reductions in catheter-related bloodstream infections (CRBSI) and related hospitalizations in hemodialysis patients [1][3]. Company Overview - CorMedix is a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases, particularly through its product DefenCath, aimed at preventing CRBSI in adult hemodialysis patients [5][6]. - The company has expanded its portfolio following the acquisition of Melinta Therapeutics LLC, which includes various anti-infective products [5][6]. Study Details - The real-world evidence study, initiated in July 2024, aims to assess the impact of DefenCath on CRBSI rates and hospitalizations over a two-year period, with over 3,000 patients currently using the product monthly at U.S. Renal Care facilities [2][3]. - Preliminary analysis indicates a 72% reduction in CRBSI and a 70% reduction in hospitalizations due to CRBSI compared to historical controls, highlighting the potential cost savings for the healthcare system [3]. Economic Impact - The Centers for Medicare & Medicaid Services (CMS) spends over $3 billion annually on CRBSI-related costs in the end-stage renal disease (ESRD) patient population, with average hospitalization costs estimated at $63,000, potentially rising to $110,000 per incident [3]. - CorMedix aims to leverage these findings in discussions with payers, including Medicare Advantage, to enhance access to DefenCath and establish long-term reimbursement strategies [4]. Future Directions - The company is also assessing secondary data points such as missed treatment sessions and antibiotic utilization, with plans to release additional real-world evidence data in the future [4]. - CorMedix continues to conduct clinical studies for DefenCath in other patient populations and intends to develop it as a catheter lock solution [7].